BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20089965)

  • 1. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
    Asslaber D; Piñón JD; Seyfried I; Desch P; Stöcher M; Tinhofer I; Egle A; Merkel O; Greil R
    Blood; 2010 May; 115(21):4191-7. PubMed ID: 20089965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.
    Merkel O; Asslaber D; Piñón JD; Egle A; Greil R
    Cell Cycle; 2010 Jul; 9(14):2764-8. PubMed ID: 20581456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
    Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
    Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY
    Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
    Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia.
    Yang YQ; Tian T; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Wang L; Fan L; Li JY; Xu W
    BMC Cancer; 2018 Oct; 18(1):1009. PubMed ID: 30348117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
    Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
    Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations.
    Li Y; Mao M; Liu H; Wang X; Kou Z; Nie Y; Wang Y; Wang Z; Huang Q; Lang T; Gu Z; An L; Zhang X; Fu L
    Mol Cell Probes; 2019 Oct; 47():101436. PubMed ID: 31425738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
    Lahiri O; Harris S; Packham G; Howell M
    Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
    Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
    JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.
    Zou ZJ; Fan L; Wang L; Xu J; Zhang R; Tian T; Li JY; Xu W
    Oncotarget; 2015 Jan; 6(2):1276-85. PubMed ID: 25361012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
    Cerna K; Oppelt J; Chochola V; Musilova K; Seda V; Pavlasova G; Radova L; Arigoni M; Calogero RA; Benes V; Trbusek M; Brychtova Y; Doubek M; Mayer J; Pospisilova S; Mraz M
    Leukemia; 2019 Feb; 33(2):403-414. PubMed ID: 30111844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.
    Seyfried I; Hofbauer S; Stoecher M; Greil R; Tinhofer I
    Blood; 2008 Sep; 112(5):2168; author reply 2169. PubMed ID: 18725577
    [No Abstract]   [Full Text] [Related]  

  • 16. [The expression and prognostic significance of microRNA-34a in Uygur and Han patients with chronic lymphocytic leukemia in Xinjiang Uygur Autonomous Region in China].
    Liu H; Wang XM; Mao M; Fu L; Huang Q; Wang YL; Wang YC; Wang ZS; Li Y
    Zhonghua Nei Ke Za Zhi; 2018 Dec; 57(12):922-925. PubMed ID: 30486562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia: molecular genetics and animal models.
    Pekarsky Y; Calin GA; Aqeilan R
    Curr Top Microbiol Immunol; 2005; 294():51-70. PubMed ID: 16323427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Balatti V; Tomasello L; Rassenti LZ; Veneziano D; Nigita G; Wang HY; Thorson JA; Kipps TJ; Pekarsky Y; Croce CM
    Blood; 2018 Nov; 132(20):2179-2182. PubMed ID: 30242085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
    Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
    Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.